asetype a plus sign (+) inside this box —	→ 🛨	Approved	for use through 10/31/2002. OMB 0651-0031 Office: U.S. DEPARTMENT OF COMMERCE	
ase type a plus sign (*) meses	rsons are re	quired to respond to a collection of inform	Office: U.S. DEPARTMENT OF COMMENT OF A control number. ation unless it displays a valid OMB control number.	
<del>3</del>		Application Number	U9/042,USA	
TRANSMITTAL,		Filing Date	August 18, 2000 SEP 3 0 2	
FORM		First Named Inventor	MACK	
to be used for all correspondence after initial filing)		Group Art Unit	1653 TECH CENTER (	
be used for all correspondence area and		Examiner Name	Schnizer, Holly G.	
al Number of Pages in This Submission	111	Attorney Docket Number	018501-009700US	
al Number of Pages III This Gustiment	ENCL	OSURES (check all that apply)		
	Assig	nment Papers	After Allowance Communication to Group	
Fee Transmittal Form	(for ar	Application)	Appeal Communication to Board of	
Fee Attached	☐ Draw	ing(s)	Appeals and Interrerences	
Amendment / Reply	Licer	sing-related Papers	(Appeal Notice, Brief, Reply Brief)	
After Final Petit		on	Proprietary Information	
		ion to Convert to a risional Application	Status Letter	
Affidavits/declaration(s)	ł	er of Attorney, Revocation	Other Enclosure(s)	
Extension of Time Request  Express Abandonment Request		nge of Correspondence Address	(please identify below):	
		ninal Disclaimer	Return Postcard; Comm. Under 37 CFR	
		uest for Refund	1.821-1.825 and Amendment; Seq. Diskette; printed sequence pages1-6; copy	
☐ Information Disclosure Statement	I —		of Notice.	
Certified Copy of Priority Document(s)		The Commissioner Deposit Account 20	is authorized to charge any additional fees to 0-1430.	
Response to Missing Parts/				
Incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				
CICL CICL	ATURE	OF APPLICANT, ATTORNEY	, OR AGENT	
Townsend and	ownsend	and Crew LLP		
and Annette S. Pare		Reg	J. No. 42,058	
Individual name	111	186		
Signature		<i>//</i>	<del></del>	
Date September 16,	2002 			
		CERTIFICATE OF MAILING	Doctal Service with sufficient postage as man	
I hereby certify that this correspondent class mail in an envelope addressed to	ce is being o: Commis		Postal Service with sufficient postage as first 0.C. 20231 on this date: September 16, 2002	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO. 09/642,034	FILING DATE 08/18/2000	FIRST NAMED INVENTOR  David Mack	A-69195/RMS/DAV/JJD	CONFIRMATION NO. 6513	
20350 7590 08/16/2002 TOWNSEND AND TOWNSEND A TWO EMBARCADERO CENTER		AND CREW, LLP	EXAMINER SCHNIZER, HOLLY G		
CITTITIO	OOR CISCO, CA 94111-3834		1653 DATE MAILED: 08/16/2002	PAPER NUMBER	

Response Due SEQUENCE 9/16/02 ALB

Please find below and/or attached an Office communication concerning this application or proceeding.

## APPLICANT COPY



Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

PATES OF P			
THURS DATE IN	FIRST NAMED	APPLICANT ATT	ORNEY DOCKET NO.
SERIAL NUMBER FILING DATE '			
09/642,034	1	EXAN	MINER
PE JCS		Holly Schnizer  ART UNIT	PAPER NUMBER
ATTENT & TRIBERT	J	1653 DATE MAILED:	10
PATENT & TRIBET			CENI

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With 1.821 through 1.825 for Patent Applications Containing Nucleotide Sequence And/Or Amino Requirements For Patent Applications Containing Nucleotide Sequence Iisting in the instant Acid Sequence Disclosures. If Applicant desires the sequence listing in the instant application to be identical with that of another application on file in the Patent and Trademark Office, such request in accordance with 37 C.F.R. 1.821(e) may be submitted in lieu of a new CRF.

APPLICANT IS GIVEN A <u>ONE</u> MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case accompanied by the extension fee under the provisions of the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Examiner Holly Schnizer, Art Unit 1653, whose telephone number is 703-305-3722. The examiner can normally be reached Mon. and Thurs. from 8 am to 5:30 pm and Tues. and Wed. from 9 am to 2:30 pm. I attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christopher Low can be reached at 703-308-2923.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

HS Holly SCHMIZER August 14, 2002

SABRIELLE BUGAISKY

Application No.: 09/642,034 WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING QUÉNCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

ne req	ulle	ments to 02.0 E.B. 1.821-1.825 Applicant's
X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG attention is directed to the final rulemaking notice published at 55 FR 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
X	2.	$\frac{1}{100} = \frac{1}{100} = \frac{1}$
X		A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as the computer readable form has been submitted. However, the content of the computer readable form has been submitted. However, the content of the computer readable form has been submitted. However, the content of the computer readable form has been submitted. However, the content of the computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as the computer readable form does not comply with the requirements of the computer readable form does not comply with the requirements of the computer readable form does not comply with the requirements of the computer readable form does not comply with the requirements of the computer readable form does not comply with the requirements of the computer readable form does not compute the computer readable form does not com
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer and the form must be submitted as required by 37 C.F.R. 1.825(d).
	6	*Sequence Listing" is not the same as the computer readable from or the
	7	. Other: _
		Applicant Must Provide:
X	ļ	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
	1 /	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its only when
X	1	the specification.
X	) '	A statement that the content of the paper and computer readable oppositely.  Include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For Patentin software Program Support:
  - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
  - Email: PATIN21HELP@uspto.gov
  - To purchase Patentin sofftware: (703) 306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE